Search Results - "PODHOREC, JAN"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Identification of AGR2 Gene-Specific Expression Patterns Associated with Epithelial-Mesenchymal Transition by Martisova, Andrea, Sommerova, Lucia, Krejci, Adam, Selingerova, Iveta, Kolarova, Tamara, Zavadil Kokas, Filip, Holanek, Milos, Podhorec, Jan, Kazda, Tomas, Hrstka, Roman

    “…The TGF-β signaling pathway is involved in numerous cellular processes, and its deregulation may result in cancer development. One of the key processes in…”
    Get full text
    Journal Article
  2. 2

    Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients by DOBES, PETR, PODHOREC, JAN, COUFAL, OLDRICH, JURECKOVA, ANDREA, PETRAKOVA, KATARINA, VOJTESEK, BORIVOJ, HRSTKA, ROMAN

    Published in Oncology reports (01-10-2014)
    “…High rates of mutation in the TP53 tumor suppressor gene have been found in many human cancers, including breast tumors, making p53 one of the most studied…”
    Get full text
    Journal Article
  3. 3

    Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment by Bouchalova, Pavla, Beranek, Jindrich, Lapcik, Petr, Potesil, David, Podhorec, Jan, Poprach, Alexandr, Bouchal, Pavel

    Published in Biomedicines (03-09-2021)
    “…Renal cell carcinoma (RCC) represents about 2–3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine…”
    Get full text
    Journal Article
  4. 4

    A large‐scale assay library for targeted protein quantification in renal cell carcinoma tissues by Lapcik, Petr, Janacova, Lucia, Bouchalova, Pavla, Potesil, David, Podhorec, Jan, Hora, Milan, Poprach, Alexandr, Fiala, Ondrej, Bouchal, Pavel

    Published in Proteomics (Weinheim) (01-04-2022)
    “…Renal cell carcinoma (RCC) represents 2.2% of all cancer incidences; however, prognostic or predictive RCC biomarkers at protein level are largely missing. To…”
    Get full text
    Journal Article
  5. 5

    SWATH-MS Analysis of FFPE Tissues Identifies Stathmin as a Potential Marker of Endometrial Cancer in Patients Exposed to Tamoxifen by Janacova, Lucia, Faktor, Jakub, Capkova, Lenka, Paralova, Vendula, Pospisilova, Anna, Podhorec, Jan, Ebhardt, Holger Alexander, Hrstka, Roman, Nenutil, Rudolf, Aebersold, Ruedi, Bouchal, Pavel

    Published in Journal of proteome research (02-07-2020)
    “…A specific form of endometrial cancer (EC) can develop in breast cancer patients previously treated with tamoxifen (ET), an antagonist of estrogen receptor…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Acetylsalicylic Acid and its Potential for Chemoprevention of Colorectal Carcinoma by Ján, Podhorec, Roman, Hrstka, Ondřej, Bílek, Štěpán, Tuček, Jiří, Navrátil, Eva, Michalová, Bořivoj, Vojtěšek

    “…Non-steroidal anti-inflammatory drugs (NSAID) represent a group of medicaments inhibiting cyclooxygenase (COX) enzyme, and, in parallel, these drugs show also…”
    Get more information
    Journal Article
  8. 8

    ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells by Holcakova, Jitka, Nekulova, Marta, Orzol, Paulina, Nenutil, Rudolf, Podhorec, Jan, Svoboda, Marek, Dvorakova, Petra, Pjechova, Mariana, Hernychova, Lenka, Vojtesek, Borivoj, Coates, Philip J.

    Published in Breast cancer research and treatment (01-06-2017)
    “…Purpose The basal-A subtype of triple-negative breast cancer is characterized by high levels of ΔNp63. Various functions have been proposed for p63 in breast…”
    Get full text
    Journal Article
  9. 9

    Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells by Hrstka, Roman, Podhorec, Jan, Nenutil, Rudolf, Sommerova, Lucia, Obacz, Joanna, Durech, Michal, Faktor, Jakub, Bouchal, Pavel, Skoupilova, Hana, Vojtesek, Borivoj

    Published in Cancer investigation (28-05-2017)
    “…Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in…”
    Get full text
    Journal Article
  10. 10

    AGR2 silencing contributes to metformin‑dependent sensitization of colorectal cancer cells to chemotherapy by Martisova, Andrea, Sommerova, Lucia, Kuricova, Katarina, Podhorec, Jan, Vojtesek, Borivoj, Kankova, Katerina, Hrstka, Roman

    Published in Oncology letters (01-11-2019)
    “…There is growing epidemiological evidence indicating an association between diabetes mellitus and the increased incidence of colorectal cancer (CRC). The…”
    Get full text
    Journal Article
  11. 11

    Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients by Obacz, Joanna, Brychtova, Veronika, Podhorec, Jan, Fabian, Pavel, Dobes, Petr, Vojtesek, Borivoj, Hrstka, Roman

    Published in OncoTargets and therapy (2015)
    “…Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3…”
    Get full text
    Journal Article
  12. 12

    Np63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells by Holcakova, Jitka, Nekulova, Marta, Orzol, Paulina, Nenutil, Rudolf, Podhorec, Jan, Svoboda, Marek, Dvorakova, Petra

    Published in Breast cancer research and treatment (01-06-2017)
    “…Purpose The basal-A subtype of triple-negative breast cancer is characterized by high levels of [DELTA]Np63. Various functions have been proposed for p63 in…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment by Bílek, O, Holánek, M, Berkovcová, J, Horký, O, Kazda, T, Čoupková, H, Špelda, S, Kristková, L, Zvaríková, M, Podhorec, J, Bořilová, S, Bohovicová, L, Zdražilová Dubská, L

    “…Epidermal growth factor receptor (EGFR) mutations play an important role in the pathogenesis of non-small cell lung cancer. Because these alterations are…”
    Get more information
    Journal Article
  15. 15

    Malignant melanoma treated with radical chemotherapy, resemblance histology of melanoma to soft tissue sarcomas, case report by Bílek, O, Tuček, S, Veselý, K, Fabian, P, Robešová, B, Adámková Krákorová, D, Lakomý, R, Svoboda, M, Jurečková, A, Halámková, J, Králová, J, Sikulíncová, L, Podhorec, J, Tomášek, J, Kiss, I, Vyzula, R

    Published in Klinická onkologie (2013)
    “…Malignant melanoma is considered to be highly resistant to chemotherapy, radiotherapy, hormonotherapy and standard immunotherapy (interleukin 2, interferon…”
    Get more information
    Journal Article